Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.
Lucia NogovaChristian MattonetMatthias SchefflerMax TaubertMasyar GardiziMartin L SosSebastian MichelsRieke N FischerMeike LimburgDiana S Y AbdullaThorsten PersigehlCarsten KobeSabine Merkelbach-BruseJeremy FranklinHeiko BackesRoland SchnellDirk BehringerBritta KaminskyMartina EichstaedtChristoph StelzerMartina KinzigFritz SörgelYingying TianLisa JungeAhmed A SuleimanSebastian FrechenDennis RokittaDongsheng OuyangUwe FuhrReinhard BuettnerJürgen WolfPublished in: Cancer medicine (2020)
Treatment of patients with relapsed solid tumors with 7.5 mg/d E and 800 mg/d S is safe and feasible. Early metabolic response in FDG-PET was not confirmed in CT scan several weeks later. The combination of S and E is obviously not sufficient to induce durable responses in patients with KRAS-mutant solid tumors.
Keyphrases
- positron emission tomography
- pet ct
- computed tomography
- wild type
- pet imaging
- small cell lung cancer
- acute lymphoblastic leukemia
- dual energy
- acute myeloid leukemia
- clinical trial
- contrast enhanced
- multiple myeloma
- magnetic resonance imaging
- image quality
- phase iii
- advanced non small cell lung cancer
- randomized controlled trial
- magnetic resonance
- phase ii
- combination therapy
- gestational age
- brain metastases
- clinical evaluation